Role of general practitioners in promoting and monitoring of hormone eplacement therapy (HRT) among climacteric women in Lublin Voivodeship in 2006–2007
Introduction: The study presents the results of research on the practical health care implementation for climacteric women by general
practitioners in Lublin Voivodeship.
Aim: The aim of this study was to assess the use of hormone replacement therapy among climacteric women by general
practitioners in Lublin Voivodeship.
Material and Methods: Data were obtained from general practitioners who completed a questionnaire about, inter alia, ways of medical practices
during the perimenopausal period and the role of general practitioners in the provision of health care for climacteric
women. They were also asked about knowledge concerning indications and contraindications to hormone replacement
therapy and the reasons for deciding on its use. A questionnaire designed by the authors was used in the epidemiological
study. Research was conducted in 2006–2007 in the Department of Internal Diseases at the Medical University in Lublin.
The study involved 45 general practitioners working in primary health care in Lublin Voivodeship.
Based on own study, it was confirmed that general practitioners’ interest in the perimenopausal symptoms diagnostics and hormone replacement therapy monitoring is insufficient
Results: Currently, a general practitioner in Lublin Voivodeship is the
weakest link in the health care system when dealing with the diagnostics of the perimenopausal period and monitoring
hormone replacement therapy. This situation results from the range of specialized training and competences conferred
on a general practitioner by the National Health Fund.
Conclusions: The presented results may be used in the health care system reorganization and directly at the level of medical practice.
Improving health care for women during menopause by general practitioners requires the organization of additional
training and updating of knowledge in this area.
REFERENCES(36)
1.
Bińkowska M, Pietrzak B, Dębski R. Hormonalna terapia zastępcza w grupie kobiet polskich w wieku 45–54 lat. Wiedza, opinia, stosowanie. Przegl Menopauzal. 2005; 2: 19–27.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML i wsp. Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288: 321–233.
Spaczyński M. Wprowadzenie do Rekomendacji Zarządu Głownego PTG w sprawie stosowania hormonalnej terapii zastępczej (Stan wiedzy na dzień 10.07.2004 r. – prof. dr hab. n. med. Tomasz Pertyński) Ginekol Prakt. 2004; 4: 2–4.
Pertyński T, Stachowiak G, Stetkiewicz T, Faflik U. Wpływ przezskórnej terapii hormonalnej na ryzyko zakrzepowo-zatorowe u kobiet w okresie menopauzy. Przegl Menopauzal. 2006; 2: 92–95.
Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS i wsp. Women’s Health Initiative Investigators.: Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004; 292: 1573–1580.
Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B i wsp. Effect of oestrogen during menopause on risk and age at onset of Alzheimer disease. Lancet. 1996; 348: 429–432.
Herrington DM, Reboussin DM, Klein KP, Sharp PC, Shumaker SA, Snyder TE i wsp. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin Trials. 2000; 21: 257–285.
Woźniakowska E, Milart P, Woźniak S, Wrona W, Szkodziak P, Paszkowski M, Czuczwar P, Paszkowski T. Standardy hormonalnej terapii zastępczej po Women’s Health Initiative – przegląd najnowszych doniesień dotyczących znaczenia drogi podania dla profilu bezpieczeństwa terapii. Przegl. Menopauzal. 2013; 1: 83–86.
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13): 1465–77.
Stachowiak P, Jastrzębska B, Motyl O,Michalska M, Kardyńska K, Pelczarska M, Bielińska I, Przybycień K. Ocena wpływu hormonalnej terapii zastępczej na występowanie choroby wieńcowej po 8 latach obserwacji. Folia Cardiologica Excerpta. 2010; 5(6): 388–393.
Panay N. Does hormone replacement therapy cause breast cancer? Commentary on Shapiro et al. papers, Parts 1–5. Journal of Family Planning and Reproductive Health Care. 2013; 0: 1–3.
Kornacewicz-Jach Z, Czarnecka D, Rynkiewicz A, Kotarski J, Paszkowski T, Pertyński T i wsp. Stanowisko zespołu ekspertow Polskiego Towarzystwa Ginekologicznego, Polskiego Towarzystwa Kardiologicznego oraz Polskiego Towarzystwa Menopauzy i Andropauzy na temat wpływu terapii hormonalnej okresu menopauzalnego na układ sercowo-naczyniowy. Kardiol Pol. 2009; 67: 72–76.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.